Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 11/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491533 | 0.83 | GPR119 (0.48) | PIK3CDGPR119KDM1APIK3CAPIK3CB | |
| SCHEMBL22608974 | 0.82 | IDO1 (0.50) | PIK3CDIDO1TDO2PDE4BPARP1 | |
| SCHEMBL14202662 | 0.81 | PIK3CD (0.51) | PIK3CDGPR119KDM1APIK3CAPIK3CB | |
| SCHEMBL17739093 | 0.81 | CYP4F2 (0.48) | PIK3CAPARP1 | |
| SCHEMBL5416839 | 0.81 | PIK3CD (0.47) | PIK3CDIDO1TDO2PIK3CAPIK3CB | |
| SCHEMBL27232265 | 0.81 | PIK3CD (0.52) | PIK3CDIDO1TDO2PIK3CAPIK3CB | |
| SCHEMBL27228977 | 0.81 | PIK3CD (0.52) | PIK3CDIDO1TDO2PIK3CAPIK3CB | |
| SCHEMBL5462157 | 0.77 | STS (0.51) | PIK3CDGPR119KDM1APIK3CAPIK3CB | |
| SCHEMBL1927899 | 0.77 | USP30 (0.52) | PIK3CDGPR119KDM1APIK3CAPIK3CB | |
| SCHEMBL3111017 | 0.77 | RBP4 (0.57) | PIK3CDGPR119KDM1APIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | disclosed |
| US-6815456-B2 | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-11-09 | — | — | US | disclosed |
| EP-1385842-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-04-10 | — | — | US | disclosed |
| WO-2002085892-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | PIK3CD 4133/4885IDO1 190/4885TDO2 71/4885 |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | PIK3CD 4217/4885IDO1 176/4885TDO2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.